Linkedin
RLS logo_header
Linkedin

FDA IND Clearance Receives to Initiate Clinical Testing of R-5780 in Cancer

“The FDA’s clearance for R-5780 is a testament to the innovation and dedication of our team at Rise Therapeutics driving novel immunotherapies forward into human proof-of-concept” states Christian Furlan Freguia, Senior Vice President of Research at Rise Therapeutics. “R-5780 represents a pioneering approach that leverages the power of gut-regulated immune pathways to enhance the effectiveness of immune checkpoint inhibitors… We believe R-5780 has the potential to expand responses in patients that become refractory to immune checkpoint inhibitors and increase responsiveness in tumors initially unresponsive to these medications”.

Read the full story on "FDA IND Clearance Receives to Initiate Clinical Testing of R-5780 in Cancer"

Share:

More News

Ph 1 SB101 Trial expanded to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

“The Sonnet team has been studying the efficacy and safety of SON-1010 as a single agent, which has thus far suggested clinical benefit when administered as a monotherapy in patients with advanced solid tumors,” said Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. “Further, we believe this synergy could

New Real-World DOR Data for JELMYTO Reports 68% RFS at Three Years in Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

“We are excited by the three-year results showing the durability of JELMYTO in treating low-grade upper tract urothelial cancer, with 68% of patients remaining recurrence-free,” said Mark Schoenberg, M.D., Chief Medical Officer, UroGen. “These findings underscore the promising long-term potential of JELMYTO in managing this challenging disease. We are committed

Global Ph 3 Trial of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for 1L Recurrent Head and Neck Cancer initiated

Mickey Mikitani, Chief Executive Officer and Vice Chairman of the Board of Rakuten Medical, concluded, “The initiation of this global Phase 3 trial marks a significant milestone in our journey to contribute to the treatment and lives of patients with head and neck cancer and potentially others affected by cancer.

ASCO GI 2025: Positive Updated Data from ASPEN-06 Ph 2 Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer presented

“The results from this trial tell a clear story that when a cancer cell is expressing HER2, evorpacept can combine with a regimen containing an anti-HER2 antibody such as trastuzumab to improve upon the activity you would expect from that regimen alone,” said Alan Sandler, M.D., Chief Medical Officer at

Onco-This-Week

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.